Drug Profile
Zelminemab - Amgen/Novartis
Alternative Names: AMG-301Latest Information Update: 11 Mar 2021
Price :
$50
*
At a glance
- Originator Amgen
- Class Antimigraines; Monoclonal antibodies
- Mechanism of Action Pituitary adenylate cyclase activating polypeptide type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Migraine
Most Recent Events
- 06 Feb 2019 Amgen completes a phase II trial in Migraine (Prevention) in Austria, Denmark, Canada, Czech Republic, Finland, Germany, Netherlands, Sweden, USA (SC) (EudraCT2017-000630-57)
- 04 Jul 2017 Phase-II clinical trials in Migraine (Prevention) in Austria, Denmark, Canada, Czech Republic, Finland, Germany, Netherlands, Sweden, USA (SC) (EudraCT2017-000630-57)
- 01 Sep 2015 AMG 301 licensed to Novartis worldwide excluding, USA, Canada and Japan